Agilent Technologies (A)

The sleeper story is the two-year growth stack building durability signals while everyone fixates on the margin miss. Agilent's sequential acceleration from 1.2% to 6.1% core growth over five quarters isn't just cyclical - management explicitly called out the two-year stack improvement as evidence of 'durable momentum, not just a short-term bounce.' The margin disappointment from commercial investments and variable pay is actually validation they're capturing share during the replacement cycle. The binding constraint is no longer customer approvals (pharma moved from executive sign-offs back to lab managers) but Agilent's own commercial capacity to capture the replacement wave. CFO Rodney said it best: 'We're increasingly confident now where the double-digit full-year outlook is concerned' for NASD. My view changes if Q4 doesn't deliver the promised 230 bps sequential margin improvement or China stimulus fails to materialize.